Research ArticleTheranostics
Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer
Andrei Gafita, Isabel Rauscher, Margitta Retz, Karina Knorr, Matthias Heck, Hans-Jürgen Wester, Calogero D’Alessandria, Wolfgang A. Weber, Matthias Eiber and Robert Tauber
Journal of Nuclear Medicine May 2019, 60 (5) 644-648; DOI: https://doi.org/10.2967/jnumed.118.215715
Andrei Gafita
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Isabel Rauscher
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Margitta Retz
2Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and
Karina Knorr
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Matthias Heck
2Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and
Hans-Jürgen Wester
3Chair of Pharmaceutical Radiochemistry, Technical University of Munich, Munich, Germany
Calogero D’Alessandria
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Wolfgang A. Weber
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Matthias Eiber
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Robert Tauber
2Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 5
May 1, 2019
Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer
Andrei Gafita, Isabel Rauscher, Margitta Retz, Karina Knorr, Matthias Heck, Hans-Jürgen Wester, Calogero D’Alessandria, Wolfgang A. Weber, Matthias Eiber, Robert Tauber
Journal of Nuclear Medicine May 2019, 60 (5) 644-648; DOI: 10.2967/jnumed.118.215715
Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer
Andrei Gafita, Isabel Rauscher, Margitta Retz, Karina Knorr, Matthias Heck, Hans-Jürgen Wester, Calogero D’Alessandria, Wolfgang A. Weber, Matthias Eiber, Robert Tauber
Journal of Nuclear Medicine May 2019, 60 (5) 644-648; DOI: 10.2967/jnumed.118.215715
Jump to section
Related Articles
Cited By...
- Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
- Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
- Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
- Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice
- Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
- Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted {alpha}-particle therapy
- Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy